Injectable hyaluronic acid for the correction of HIV‐associated facial lipoatrophy

Denton, Andrew B.; Tsaparas, Yotis

doi:10.1016/j.otohns.2006.11.049

Cited by 22 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although limited to a small number of patients, our study confirms previous observations [10,11] regarding the excellent tolerance of cross-linked HA fillers and the absence of allergic reactions or product-related complications. Significant cosmetic improvement and improved quality of life were observed in the HIV-LA patients in the current study.…”

Section: Discussionsupporting

confidence: 90%

“…Treatment strategies for HIV-associated facial lipoatrophy include soft tissue augmentation procedures performed using autologous fat grafting or injectable dermal fillers [8,9,10,11,12]. Cross-linked hyaluronic acid (HA) derivatives are non-permanent dermal fillers used not only for the correction of HIV-LA, but also for treatment of photodamaged skin [13], facial atrophic scars [14] and other cosmetic purposes [15,16,17].…”

Section: Introductionmentioning

confidence: 99%

“…Most authors assessed patient satisfaction by means of the Global Aesthetic Improvement Scale (GAIS) or the Quality of Life Assessment (QoLA) score [10,11], and only very few attempted to evaluate treatment results in a more objective manner by using ultrasonographic measurements of facial tissues [9,23]. Due to its excellent soft tissue discrimination and the possibility to obtain quantitative data, magnetic resonance imaging (MRI) is increasingly used for the evaluation of injectable dermal fillers [25].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRI

et al. 2015

View full text Add to dashboard Cite

Objective: This prospective observational study evaluated magnetic resonance imaging (MRI) findings of hyaluronic acid (HA) injections used for the correction of HIV-associated facial lipoatrophy. Methods: Ten consecutive males underwent subdermal HA injection (mean 1.3 ± 0.6 ml per side) and MRI examinations prior to and then 1, 6 and 12 months after injection. Two radiologists blinded to the clinical data assessed morphologic and quantitative changes. Results: MRI revealed HA deposition in the subdermal and deep fat compartments. A significant HA volume increase was observed 1 month after injection (mean increase 331%, p < 0.0001) as compared to the injected amount. No volume reduction occurred at 12 months (p = 0.9961). The measured bound water content did not change (p > 0.9991), whereas skin thickness and tissue vascularization increased during the first 6 months (p = 0.01). Conclusion: Our data show that the cosmetic results of HA injections are caused by water binding in the deep facial fat and by a transient increase in vascularization and skin thickness.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRI

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This decrease is explained by the production of more purified forms of hyaluronic acid by the pharmaceutical industries. 82 The hyaluronic acid has been used successfully to treat HIV facial lipoatrophy. However, as in other temporary fillings, great volumes are frequently necessary in order to achieve a complete correction, which tends to decrease after 6 to 12 months.…”

Section: Other Cutaneous Fillersmentioning

confidence: 99%

Lipoatrofia facial associada ao HIV/AIDS: do advento aosconhecimentos atuais

Soares¹,

Costa

2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

Abstract:The advent of AIDS has brought new challenges to Dermatology. Antiretroviral therapy dramatically changed the morbidity and mortality associated with HIV / AIDS, but contributed to the emergence of other new situations that require adequate approach by the dermatologist. The HIV / AIDS Associated Lipodystrophy Syndrome is multifactorial in origin, but it is strongly associated with the use of antiretroviral drugs. It includes changes in body fat distribution, with or without metabolic changes. The loss of facial fat, called facial lipoatrophy, is one of the most stigmatizing signs of the syndrome. This condition, often revealing of the disease, brought back the stigma of AIDS. It is necessary that the specialists working with patients with HIV / AIDS identify these changes and seek treatment options, amongst which stands out the implant with polymethylmethacrylate, which is available for the treatment of HIV / AIDS facial lipoatrophy in the Brazilian Public Health System. Keywords: Ambulatory surgical procedures; HIV; HIV-associated lipodystrophy syndrome; Polymethyl methacrylate; Therapeutics Resumo: O advento da AIDS trouxe novos desafios para a Dermatologia. A terapia antirretroviral mudou drasticamente a morbimortalidade associada à infecção pelo HIV/AIDS, mas contribuiu para o surgimento de outras novas situações que exigem abordagem adequada do dermatologista. A Síndrome Lipodistrófica Associada ao HIV/AIDS tem origem multifatorial, mas está fortemente associada ao uso dos antirretrovirais. Compreende alterações na distribuição da gordura corporal, acompanhada ou não de alterações metabólicas. A perda da gordura da face, chamada lipoatrofia facial, é dos sinais mais estigmatizantes da síndrome. Esta condição, muitas vezes reveladora da doença, trouxe de volta o estigma da AIDS. É necessário que os especialistas que atuam com pacientes com HIV/AIDS identifiquem estas alterações e busquem opções de tratamento, dentre as quais se destaca o implante com polimetilmetacrilato, que é disponibilizado para tratamento da lipoatrofia facial associada ao HIV/AIDS no Sistema Único de Saúde.

show abstract

“…The investigators concluded that Perlane is a feasible option for correction of facial lipoatrophy, and the procedure was well tolerated without any long-term adverse events observed. 11 Other sites. From our review, a total of 17 studies investigated hyaluronic acid filler injection at specific sites other than or in combination with nasolabial folds, including three randomized controlled trials, 12 uncontrolled clinical trials, and two cohort studies.…”

Section: Hyaluronic Acid Fillersmentioning

confidence: 99%

Facial Soft-Tissue Fillers conference: Assessing the State of the Science

Hanke

Rohrich

Busso

et al. 2011

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Injectable hyaluronic acid for the correction of HIV‐associated facial lipoatrophy

Abstract: Patient satisfaction was high, with only minor side effects and no late complications. Our findings support Perlane to be a feasible option for the provisional correction of mild to moderate facial lipoatrophy.

Cited by 22 publications

References 20 publications

Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRI

Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRI

Lipoatrofia facial associada ao HIV/AIDS: do advento aosconhecimentos atuais

Facial Soft-Tissue Fillers conference: Assessing the State of the Science

Contact Info

Product

Resources

About